Patient selection for cytoreductive nephrectomy in combination with targeted therapies or immune checkpoint...

Area of Science:

• Nephrology
• Oncology
• Surgical Oncology

Background:

• Cytoreductive nephrectomy is a treatment option for metastatic renal cell carcinoma (mRCC).
• Effective patient selection is crucial for optimizing surgical outcomes in mRCC.
• Identifying patients likely to benefit from surgery remains an area of active research.

Purpose of the Study:

• To review current data on patient selection for cytoreductive surgery in mRCC.
• To evaluate which mRCC patients are most likely to benefit from cytoreductive nephrectomy.

Main Methods:

• Review of recent studies on cytoreductive nephrectomy and patient selection.
• Analysis of individual prognostic factors and risk stratification models.
• Evaluation of serum laboratory values and tumor histology as prognostic indicators.

Main Results:

• Cytoreductive nephrectomy benefits selected mRCC patients with good performance status and favorable or intermediate-risk criteria.
• Individual prognostic factors and risk stratification models aid in survival estimation and patient selection.
• Serum labs and tumor histology have demonstrated prognostic value in mRCC.

Conclusions:

• Ideal patient selection for cytoreductive nephrectomy requires individual assessment of prognostic risk factors.
• Discussion of surgical risks and benefits is essential for informed decision-making.
• Upfront systemic therapy should be considered for poor-risk mRCC patients after multidisciplinary consultation.